Valerio Therapeutics SA 2015 IR
The report highlights Onxeo's progress in 2015 as a biotechnology company specializing in orphan oncology drugs, notably with its key programs Beleodaq, Livatag, and Validive. Key achievements include positive Phase I results for Beleodaq in combination with CHOP, and the ongoing Phase III ReLive trial for Livatag in primary liver cancer. The company also expanded its pipeline by acquiring DNA Therapeutics and its AsiDNA technology in early 2016. Onxeo maintained its commitment to social and environmental responsibility, reporting a highly feminized workforce with 69% women and implementing robust health, safety, and waste management protocols in its laboratories.
Company: Valerio Therapeutics SA
Sector: Professional & technical services
Country: France
Year: 2015
Type: IR
Pages: 231
Back to company
Valerio Therapeutics SA
Reference Document
The report highlights Onxeo's progress in 2015 as a biotechnology company specializing in orphan oncology drugs, notably with its key programs Beleodaq, Livatag, and Validive. Key achievements include positive Phase I results for Beleodaq in combination with CHOP, and the ongoing Phase III ReLive trial for Livatag in primary liver cancer. The company also expanded its pipeline by acquiring DNA Therapeutics and its AsiDNA technology in early 2016. Onxeo maintained its commitment to social and environmental responsibility, reporting a highly feminized workforce with 69% women and implementing robust health, safety, and waste management protocols in its laboratories.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Published
Apr 29, 2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees